

Martin Misch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/135710/publications.pdf>

Version: 2024-02-01

30
papers

1,530
citations

471509

17
h-index

454955

30
g-index

31
all docs

31
docs citations

31
times ranked

2401
citing authors

#	ARTICLE	IF	CITATIONS
1	Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA ⁰⁹): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 678-688.	13.7	384
2	A vaccine targeting mutant IDH1 in newly diagnosed glioma. <i>Nature</i> , 2021, 592, 463-468.	27.8	232
3	Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection. <i>Neuro-Oncology</i> , 2016, 18, 96-104.	1.2	186
4	IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2012, 21, 194-197.	2.0	123
5	Association of F18-fluoro-ethyl-tyrosin uptake and 5-aminolevulinic acid-induced fluorescence in gliomas. <i>Acta Neurochirurgica</i> , 2009, 151, 1377-1383.	1.7	67
6	No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas. <i>Journal of Neuro-Oncology</i> , 2012, 109, 15-22.	2.9	66
7	Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2010, 100, 407-415.	2.9	54
8	Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients. <i>Acta Neuropathologica Communications</i> , 2019, 7, 89.	5.2	48
9	18F-FET-PET guided surgical biopsy and resection in children and adolescence with brain tumors. <i>Child's Nervous System</i> , 2015, 31, 261-267.	1.1	47
10	The effect of traumatic brain injury on bone healing: an experimental study in a novel in vivo animal model. <i>Injury</i> , 2015, 46, 661-665.	1.7	45
11	Adjuvant radiotherapy improves progression-free survival in intracranial atypical meningioma. <i>Radiation Oncology</i> , 2019, 14, 160.	2.7	30
12	Safety and Tolerance of D,L-Methadone in Combination with Chemotherapy in Patients with Glioma. <i>Anticancer Research</i> , 2017, 37, 1227-1236.	1.1	29
13	Monitor-based exoscopic 3D4k neurosurgical interventions: a two-phase prospective-randomized clinical evaluation of a novel hybrid device. <i>Acta Neurochirurgica</i> , 2020, 162, 2949-2961.	1.7	27
14	Acceptance and compliance of TTFields treatment among high grade glioma patients. <i>Journal of Neuro-Oncology</i> , 2018, 139, 177-184.	2.9	26
15	Clinical implementation of a 3D4K-exoscope (Orbeye) in microneurosurgery. <i>Neurosurgical Review</i> , 2022, 45, 627-635.	2.4	23
16	T2 mapping of molecular subtypes of WHO grade II/III gliomas. <i>BMC Neurology</i> , 2020, 20, 8.	1.8	22
17	Impact of postoperative radiotherapy on recurrence of primary intracranial atypical meningiomas. <i>Journal of Neuro-Oncology</i> , 2020, 146, 347-355.	2.9	20
18	The Impact of Tumor Treating Fields on Glioblastoma Progression Patterns. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 1269-1278.	0.8	20

#	ARTICLE	IF	CITATIONS
19	Molecular characterization of CNS paragangliomas identifies cauda equina paragangliomas as a distinct tumor entity. <i>Acta Neuropathologica</i> , 2020, 140, 893-906.	7.7	19
20	Locally dose-escalated radiotherapy may improve intracranial local control and overall survival among patients with glioblastoma. <i>Radiation Oncology</i> , 2018, 13, 251.	2.7	13
21	AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas. <i>Neurological Research and Practice</i> , 2022, 4, .	2.0	13
22	Patient Reported Outcome (PRO) Among High-Grade Glioma Patients Receiving TTFIELDS Treatment: A Two Center Observational Study. <i>Frontiers in Neurology</i> , 2019, 10, 1026.	2.4	11
23	Glioma patients in outpatient care – optimization of psychosocial care in neuro-oncological patients (GLIOPT): Protocol for a cluster randomized controlled trial. <i>Trials</i> , 2020, 21, 434.	1.6	5
24	Prevention of secondary ischemic events by superficial temporal artery – middle cerebral artery bypass surgery after tuberculosis-induced vasculopathy in a 5-year-old child. <i>Journal of Neurosurgery: Pediatrics</i> , 2010, 6, 69-72.	1.3	4
25	T2 mapping of the peritumoral infiltration zone of glioblastoma and anaplastic astrocytoma. <i>Neuroradiology Journal</i> , 2021, 34, 392-400.	1.2	4
26	The Effect of Ubiquitin on Immune Response After Controlled Cortical Impact Injury. <i>Journal of Trauma</i> , 2011, 70, 1104-1111.	2.3	3
27	Optical Characterization of Sodium Fluorescein In Vitro and Ex Vivo. <i>Frontiers in Oncology</i> , 2021, 11, 654300.	2.8	3
28	Multivariable non-invasive association of isocitrate dehydrogenase mutational status in World Health Organization grade II and III gliomas with advanced magnetic resonance imaging T2 mapping techniques. <i>Neuroradiology Journal</i> , 2020, 33, 160-168.	1.2	2
29	Correlation of Tumor Pathology with Fluorescein Uptake and MRI Contrast-Enhancement in Stereotactic Biopsies. <i>Journal of Clinical Medicine</i> , 2022, 11, 3330.	2.4	2
30	HOUT-06. TTFIELDS FOR NEWLY DIAGNOSED GLIOBLASTOMA: IMPACT OF CONSULTATION STRATEGY. <i>Neuro-Oncology</i> , 2017, 19, vi107-vi107.	1.2	1